bimagrumab + tirzepatide

Bimagrumab + tirzepatide is an investigational combination therapy for obesity and weight management. Bimagrumab is a fully human monoclonal antibody that targets activin type II receptors, blocking ligands such as myostatin, activins, and GDF11 to promote skeletal muscle growth and reduce fat mass. Tirzepatide is a synthetic peptide that acts as a dual agonist at the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide 1 (GLP-1) receptor, stimulating insulin secretion in a glucose-dependent manner, reducing glucagon levels, delaying gastric emptying, decreasing food intake, and promoting weight loss. The combination aims to leverage complementary mechanisms—bimagrumab’s direct effects on adipose tissue and muscle with tirzepatide’s incretin-based metabolic actions—to enhance efficacy in treating obesity[1][4][7][8].